Experts advise against routine bowel cancer testing for all over-50s

October 02, 2019

Routine testing for bowel cancer should not be recommended for everyone aged 50-79 years because, for those at very low risk, the benefit is small and uncertain and there are potential harms, say a panel of international experts in The BMJ today.

But they say screening should be recommended for men and women with a risk of 3% or more in the next 15 years, as this is the point at which the balance of benefits and harms tilts in favour of screening.

Their advice is based on the latest evidence and is part of The BMJ's 'Rapid Recommendations' initiative - to produce rapid and trustworthy guidance based on new evidence to help doctors make better decisions with their patients.

Bowel (colorectal) cancer is a common type of cancer in men and women - about 1 in 20 people in most high income countries will get it during their lifetime. A person's risk depends on their age, sex, genetics and lifestyle factors, such as alcohol intake, smoking, physical activity and diet.

Most guidelines recommend screening for everyone from age 50, irrespective of their individual risk. At this age, the risk of developing bowel cancer over the next 15 years is typically 1-2%, meaning that in a group of 100 people with the same risk factors, one or two will develop bowel cancer within the next 15 years.

The four most common screening options are home faecal testing (FIT) every year or every two years, sigmoidoscopy (examination of the lower colon) or colonoscopy (examination of the entire colon) done at a clinic or hospital.

Recently published research on the long term effects of bowel cancer screening has shed new light on the benefits and harms, and has the potential to change current recommendations.

So an international panel made up of researchers, clinicians and patients, reviewed the evidence base, including this new evidence, to evaluate the benefit-to-harm balance of screening using a "risk based approach."

This means they took account of an individual's cumulative risk of bowel cancer over the next 15 years together with risk of harm from the procedure (e.g. bowel perforations, unnecessary treatment) and quality of life (e.g. anxiety, burden of procedure), as well as a person's values, preferences, and life expectancy.

Their recommendations apply to healthy individuals aged 50-79 years with a life expectancy of at least 15 years.

For men and women with an estimated 15-year bowel cancer risk below 3%, they suggest no screening, and say most informed individuals in this group are likely to decline screening.

However, for men and women with an estimated 15-year bowel cancer risk above 3%, they suggest screening with one of the four options, and say most informed individuals in this group are likely to choose screening after discussing the potential benefits and harms with their doctor.

The panel does not recommend any one test over another, but they found convincing evidence that people's values and preferences on whether to test and what test to have varies considerably.

For example, some people will want to avoid an invasive test like colonoscopy, and may prefer faecal testing. While those who most value preventing bowel cancer or avoiding repeated testing are likely to choose sigmoidoscopy or colonoscopy.

The authors stress that there are still many uncertainties in terms of what is the most effective screening test or combination of tests, and at what age and interval they should be used, and suggest this should be the focus of future research. These recommendations may also be altered as new evidence emerges, they conclude.

The evidence backing colorectal cancer screening "is still fragile and strong recommendations cannot be issued at the moment," writes Professor Philippe Autier at the International Prevention Research Institute (iPRI) in a linked editorial.

He welcomes the shift away from maximizing uptake of screening to a personalised approach based on individual risk and informed choice, which he says has several advantages over offering screening to everyone in eligible age groups.

He also acknowledges that new research is warranted for refining risk based recommendations, and says "better knowledge of risk factors associated with late stage at diagnosis and colorectal cancer death is likely to improve risk based approaches."
-end-
Externally peer-reviewed? Yes (research, practice guideline), No (linked editorial)

Type of evidence: Evaluation of randomised trials and modelling studies

Subjects: People

BMJ

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.